Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Tijmen van der Wel, MD"'
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 12, Pp 100730- (2024)
RET fusion-positive NSCLC accounts for 1% to 2% of lung carcinoma cases. Although two Food and Drug Administration–approved selective RET inhibitors, pralsetinib, and selpercatinib, have revealed efficacy in managing RET fusion-positive NSCLC, this
Externí odkaz:
https://doaj.org/article/b85dc2fa0d424aee88a8beffee93b8fd
